Stephen Hawser
Overview
Explore the profile of Stephen Hawser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
718
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hawser S, Morrissey I, Kothari N, Monti F, Santerre Henriksen A
J Glob Antimicrob Resist
. 2024 Sep;
39:137-143.
PMID: 39278462
Objectives: To support the clinical development of mecillinam and pivmecillinam in the United States for the treatment of complicated and uncomplicated urinary tract infections (UTIs), this study investigated the activity...
2.
Morrissey I, Hawser S, Kothari N, Dunkel N, Quevedo J, Belley A, et al.
J Glob Antimicrob Resist
. 2024 May;
38:71-82.
PMID: 38723712
Objectives: This study was performed to investigate the activity of the novel ß-lactam/ß-lactamase inhibitor combination cefepime/enmetazobactam, against recently circulating Enterobacterales isolates from Europe from 2019 to 2021. Methods: A total...
3.
Zalacain M, Achard P, Llanos A, Morrissey I, Hawser S, Holden K, et al.
Antimicrob Agents Chemother
. 2024 Jan;
68(3):e0112023.
PMID: 38289044
ANT3310 is a novel broad-spectrum diazabicyclooctane serine β-lactamase inhibitor being developed in combination with meropenem (MEM) for the treatment of serious infections in hospitalized patients where carbapenem-resistant Gram-negative pathogens are...
4.
Harding S, Barnes K, Hawser S, Bentley C, Vente A
Antibiotics (Basel)
. 2023 Jul;
12(7).
PMID: 37508192
This study determined the activity of finafloxacin against panels of bacterial strains, representative of those associated with infection in cystic fibrosis patients and predominately isolated from clinical cases of respiratory...
5.
Hawser S, Kothari N, Monti F, Morrissey I, Siegert S, Hodges T
J Glob Antimicrob Resist
. 2023 May;
33:304-320.
PMID: 37207925
Objectives: To evaluate eravacycline (ERV) activity against Gram-negative and Gram-positive bacteria collected between 2017 and 2020 from worldwide locations. Methods: MIC determinations were performed using Clinical and Laboratory Standards Institute...
6.
Michaeli J, Mandel S, Maximov S, Zazoun J, Savoia P, Kothari N, et al.
Antibiotics (Basel)
. 2022 Sep;
11(9).
PMID: 36139979
The rapid worldwide spread of antimicrobial resistance highlights the significant need for the development of innovative treatments to fight multidrug-resistant bacteria. This study describes the potent antimicrobial activity of the...
7.
Huang D, Brothers K, Mandell J, Taguchi M, Alexander P, Parker D, et al.
PLoS One
. 2022 Sep;
17(9):e0274815.
PMID: 36112657
The absence of novel antibiotics for drug-resistant and biofilm-associated infections is a global public health crisis. Antimicrobial peptides explored to address this need have encountered significant development challenges associated with...
8.
Hawser S, Kothari N, Jemmely N, Redder N
J Glob Antimicrob Resist
. 2022 May;
29:393-397.
PMID: 35561977
Objectives: Ceftobiprole is approved for use in treatment of hospital-associated and community-acquired pneumonia in 16 different European countries and is currently undergoing clinical trials in the United States. Methods: Isolates...
9.
Murugaiyan J, Kumar P, Rao G, Iskandar K, Hawser S, Hays J, et al.
Antibiotics (Basel)
. 2022 Feb;
11(2).
PMID: 35203804
Antibiotic resistance, and, in a broader perspective, antimicrobial resistance (AMR), continues to evolve and spread beyond all boundaries. As a result, infectious diseases have become more challenging or even impossible...
10.
Hawser S, Kothari N, Jemmely N, Redder N
J Glob Antimicrob Resist
. 2021 Jul;
26:326-329.
PMID: 34329790
Objectives: Ceftobiprole is approved for the treatment of hospital-acquired and community-acquired pneumonia in 17 different European countries and is currently undergoing clinical trials in the USA. Methods: In this study,...